2ad29abde43949ae94cf961444f5bfdb

31
Curriculum Vitae Steven J. Feigenberg, MD Professor Director of Clinical Research Director of the Stereotactic Body Radiotherapy Program University of Maryland School of Medicine Department of Radiation Oncology Date: December, 2013 Contact Information 22 South Greene Street Baltimore, MD 21201 Telephone: (410) 328-2328 Fax: (410) 328-6911 [email protected] Education 1991 B.S., Chemical Engineering with Chemistry minor, Drexel University (Cum Laude) 1997 M.D., Hahnemann University School of Medicine Post Graduate Education 6/1997 – 6/1998 Internship, Temple University 6/1998 – 6/2002 Residency, Radiation Oncology, University of Florida Certification 2002 American Board of Radiology, Radiation Oncology 2012 American Board of Radiology, Radiation Oncology (recertified) Medical Licensure Active Maryland Active Pennsylvania Inactive Florida Employment History Academic Appointments 2002 - 2008 Associate Member (Assistant Professor equivalent), Radiation Oncology, Fox Chase Cancer Center 2008 - 2009 Member (Associate Professor equivalent), Radiation Oncology,

Upload: larry-roberts

Post on 06-Mar-2016

213 views

Category:

Documents


1 download

DESCRIPTION

http://medschool.umaryland.edu/facultyresearchprofile/uploads/2ad29abde43949ae94cf961444f5bfdb.pdf

TRANSCRIPT

Curriculum Vitae

Steven J. Feigenberg, MD Professor

Director of Clinical Research Director of the Stereotactic Body Radiotherapy Program

University of Maryland School of Medicine Department of Radiation Oncology

Date: December, 2013 Contact Information 22 South Greene Street Baltimore, MD 21201 Telephone: (410) 328-2328 Fax: (410) 328-6911 [email protected] Education 1991 B.S., Chemical Engineering with Chemistry minor, Drexel University

(Cum Laude) 1997 M.D., Hahnemann University School of Medicine Post Graduate Education 6/1997 – 6/1998 Internship, Temple University 6/1998 – 6/2002 Residency, Radiation Oncology, University of Florida

Certification 2002 American Board of Radiology, Radiation Oncology 2012 American Board of Radiology, Radiation Oncology (recertified) Medical Licensure Active Maryland Active Pennsylvania Inactive Florida Employment History Academic Appointments 2002 - 2008 Associate Member (Assistant Professor equivalent), Radiation Oncology,

Fox Chase Cancer Center 2008 - 2009 Member (Associate Professor equivalent), Radiation Oncology,

Steven J. Feigenberg, MD

-2-

Fox Chase Cancer Center 2009 - present Associate Professor, Director of Clinical Research, Director of the

Stereotactic Body Radiotherapy Program Radiation Oncology, UMSOM Professional Society Membership 1998 – present General Member, American Society of Therapeutic Radiation Oncology 1998 - present General Member, American College of Radiology 2000 - present General Member, American Society of Clinical Oncology 2002 - present General Member, American Radium Society 2003 – present General Member, European Society of Therapeutic Radiation Oncology 2011 - present General Member, American College of Radiation Oncology 2012 - present General Member, Cancer and Leukemia Group B Honors and Awards 1987-1991 Academic Dean’s List 2000 University of Florida Department of Radiation Oncology “Talken”

Award 7/2000 - 6/2002 Chief Resident 2001 Roentgen Resident/Fellow Research Award presented by the RSNA

Research and Education Foundation 5/ 2005 The LAP award of excellence for the best Radiation Oncology Article

presented by The American College of Medical Physics 2005-2006 Association of Residents in Radiation Oncology (ARRO) Teacher of the

Year Award 2006-2007 ARRO Teacher of the Year Award 2008-2009 ARRO Teacher of the Year Award 2009-2010 ARRO Educator of the Year Award

Clinical Activities at Fox Chase Cancer Center Lung Cancer

Head of clinical program in radiation oncology started in 2004 Developed institutional policies using image guidance, IMRT and initiated stereotactic body radiotherapy program at Fox Chase Cancer Center in 2003

Central Nervous System Head of clinical program in radiation oncology

Started intracranial Stereotactic radiosurgery program in 2002 (annual volume in 2009 in 50 cases per year without the aid of a neurosurgery department or emergency room)

Head and Neck Malignancies Shared clinical program in radiation oncology

Developed institutional policies using image guidance, developed atlas for IMRT and instituted weekly meetings for teaching and clinical improvements at FCCC

Prostate Cancer using IMRT and low dose rate brachytherapy

Steven J. Feigenberg, MD

-3-

Clinical Activities at University of Maryland School of Medicine Lung Cancer

Clinical lead in radiation oncology since starting in 2009 Implemented daily image guidance and IMRT for lung cancer Developed Clinical Practice Guidelines for both early and locally advanced lung cancer

Breast Cancer Clinical lead in radiation oncology since starting in 2009

Implemented technology working group to encorporate daily inter- and intra-fractional motion tracking using real-time surface matching using Vision RT. Implemented IMRT for breast cancer Developed Clinical Practice Guidelines for early stage disease

Liver Directed Therapy Co-lead of the Liver Directed Therapy Conference with Sameh Fayek Administrative Service

Institutional Service 2002 - 2009 Member of Tumor Registry Committee 2002 - 2005 Member of Response Verification Committee 2003 - 2009 Director of CT-on-RailsTM Project 2003 - 2007 Assistant Clinical Director of Prostate Risk Assessment Program 2003 - 2009 Reviewed Network Hospital Radiation Charts quarterly 2008 - 2009 Reviewer for the Imaging and Modeling Review Group

(internal pilot project grants) for FCCC 2009 - present Thoracic Tumor Board, University of Maryland School of

Medicine 2009 - present Breast Tumor Board, University of Maryland 2009 - present Liver Directed Tumor Board, University of Maryland 2009 - present Thyroid Tumor Board, University of Maryland

2009 - present Central Nervous System/Spine Tumor Board, University of Maryland 2009 - present Solid Tumor Board, University of Maryland 2009 - present Melanoma Tumor Board, University of Maryland 2009 - present Member of Cancer Review Committee, University of Maryland 2009 - present Leader of Technology Review Committee, University of Maryland 2009 - present Ad hoc Oncology reviewer for the Institutional Review Board,

University of Maryland 2009 - present Director of Clinical Research - Department of Radiation Oncology University of Maryland 2009 - present Director of Stereotactic Body Radiotherapy Program - Department

of Radiation Oncology, University of Maryland 2009 - present Member of the Radiation Oncology Executive Leadership

Committee 2009 - present “Ask the Expert”. Stereotactic Body Radiotherapy, University of

Steven J. Feigenberg, MD

-4-

Maryland 2011 - present Member of Director of Radiobiology Search Committee 2011 - present Member of Breast Program Leadership Committee 2011 - present Member of Clinical Research Oversight Committee 2012 - present Director of Emerging Technology, Department of Radiation

Oncology, UMSOM 2012 - present Member of the Medical Physics Residency Education Committee 2012 - present Committee Member of the Institutional Review Board, University

of Maryland 2012 - present Executive Committee Alternative for the School of Medicine 2012 - present Lead, Emerging Technology Steering Committee

Administrative Services

National Service 2003 - 2006 Central Nervous System Abstract reviewer for the 2003, 2004,

2005 and 2006 Annual Meeting for ASTRO 2004 - 2009 NCCN Non-Small Cell Lung Cancer Committee 2004 - present Ad Hoc Reviewer, Cancer 2004 - present Ad Hoc Reviewer, The American Journal of Clinical Oncology 2005 - present Ad Hoc Reviewer, The Oncologist 2005 - present Ad Hoc Reviewer, Clinical Orthopaedics and Related Research 2005 - present Editorial Board - American Journal of Clinical Oncology 2007 - present Ad Hoc Reviewer, International Journal of Radiation Oncology

Biology Physics 2007 - present Ad Hoc Reviewer, Brachytherapy 2007 - present American Board of Radiology item writer for the Head & Neck

section for the in-training examination 2008 - present American Board of Radiology item writer for the Lung and Bone

& Soft Tissue Section for IC/MOC exam 2008 - present Ad Hoc Reviewer, The Medical Science Monitor 2008 - present Ad Hoc Reviewer, Head & Neck 2008 - present Ad Hoc Reviewer, Radiotherapy and Oncology 2010 - present Ad Hoc Reviewer, Journal of Medical Imaging and Radiation

Oncology 2011 Moderator for Poster Discussion in Stereotactic Body

Radiotherapy and Locally Advanced Lung Cancer for 2011 Annual Meeting for ASTRO

2011 - present Ad hoc review, Practical Radiation Oncology 2011 - present Editor Frontiers in thoracic oncology 2012 - present Reviewer for ACRO Accreditation process - gastrointestinal

section 2012 - present Advisory Board Member, Applied Radiation Oncology 2012 - present Lung Cancer Abstract reviewer for the 2012 Annual Meeting for

ASTRO

Steven J. Feigenberg, MD

-5-

2012 Moderator for oral presentation in Lung Cancer at the 2012 Annual Meeting for ASTRO

2012 - present Member, Emerging Technology Monitoring Subcommittee of the Health Policy Council for ASTRO

Teaching Service 2002 to present Attending outpatient clinic - 4 days per week – 8 to 10 hr/day – one on one

with radiation oncology residents 9-12 months per year, medical student 1 to 2 months per year

2002 to present 3 to 4 – 1 hr lectures for the radiation oncology residents, 3 to 4 – 1 hr lectures per year to the medical oncology and surgical oncology fellows

Student Lectures

2009 - present Formal Lecture – Stereotactic Body Radiotherapy annually. University of

Maryland’sDepartment of Radiation Oncology - Dosimetry School.2 students per year.

2009 - present Panel Discussion with other Multi-disciplinary Team Members for the 2nd year medical students at the University of Maryland on skin cancer and breast cancer – 2-4 hours per year

2009 - present Introduction to Oncology for the 2nd year medical students at the University of Maryland– 1-2 hours per year

Specific Resident/Fellow Lectures

2002 “Post-Operative Radiation for Head and Neck Cancer”,Fox Chase Cancer Center,

Department of Radiation Oncology 2003 “Chemotherapy and Altered Fractionation for Head and Neck Cancer”,Fox Chase

Cancer Center, Department of Radiation Oncology 2003 “General Overview of Pediatric Malignancies”,Fox Chase Cancer Center,

Department of Radiation Oncology 2003 “Oligodendrogliomas”,Fox Chase Cancer Center, Department of Radiation

Oncology 2003 “Breast Cancer – Techniques and Associated Morbidity”, Fox Chase Cancer

Center, Department of Radiation Oncology 2003 “Management of the Neck in Head and Neck Cancer”, Fox Chase Cancer Center,

Department of Radiation Oncology 2004 “Current Management of Brain Metastases”, Fox Chase Cancer Center,

Department of Medical Oncology 2004 “Head and Neck Field Design”, Fox Chase Cancer Center, Department of

Radiation Oncology 2004 “Stereotactic Radiosurgery – Treatment Planning Basics””, Fox Chase Cancer

Center, Department of Radiation Oncology 2005 “Head and Neck Cases/Field Design”, Fox Chase Cancer Center, Department of

Radiation Oncology 2005 “Management of Head & Neck Cancer with radiation with and without

Chemotherapy”, Fox Chase Cancer Center, Department of Radiation Oncology

Steven J. Feigenberg, MD

-6-

2005 Management of Brain Metastasis”, Fox Chase Cancer Center, Department of Medical Oncology

2005 “Radiation Therapy for locally advanced NSCLC”, Fox Chase Cancer Center, Department of Medical Oncology

2005 “Radiation Therapy in the Management of Squamous Cell Carcinoma of the Head & Neck”, Temple University, Department of Otolaryngology. Philadelphia, PA.

2005 “Radiation therapy for Lung Cancer”, Fox Chase Cancer Center, Department of Thoracic Oncology

2006 “Radiation Therapy for locally advanced NSCLC”, Fox Chase Cancer Center, Department of Medical Oncology

2006 “Management of Brain Metastasis”, Fox Chase Cancer Center, Department of Medical Oncology

2006 “Advances in Conformal Radiation in NSCLC”, Fox Chase Cancer Center, Department of Thoracic Oncology

2006 “Management of Locally Advanced NSCLC – Definitive and Post-Operative Settings”, Fox Chase Cancer Center, Department of Radiation Oncology

2006 “Management of Squamous Cell Carcinoma of the Oropharynx: Chemotherapy and Altered fractionation”, Fox Chase Cancer Center, Department of Radiation Oncology

2007 “Stereotactic Body Radiotherapy for Lung Cancer”, Fox Chase Cancer Center, Department of Radiation Oncology

2007 “Management of Head & Neck Cancer: The role of Induction, HPV and Erythropoietin”, Fox Chase Cancer Center, Department of Radiation Oncology

2007 “The basics of management of Head & Neck Cancer”, Fox Chase Cancer Center, Department of Radiation Oncology

2007 “Radiation Therapy for locally advanced NSCLC”, Fox Chase Cancer Center, Department of Medical Oncology

2007 “Management of Brain Metastases”, Fox Chase Cancer Center, Department of Medical Oncology

2007 “The use of Radiotherapy in NSCLC in 2007”, Fox Chase Cancer Center, Department of Thoracic Oncology

2008 “Altered fractionation in the management of Head and Neck cancer” 2008 “Radiation for tumors of the central nervous system” 2008 “The basics of management of Head & Neck cancer – field design” 2009 “IMRT for Lung Cancer – the basics” 2009 “IMRT for Head and Neck Cancer – the basics” 2009 “The use of Radiotherapy in NSCLC in 2009”, Fox Chase Cancer Center,

Department of Thoracic Oncology. Philadelphia, PA 2010 “The Gamma(γ) Pod System, SBRT Protocol Development for Breast Cancer,

University of Maryland, Department of Radiation Oncology 2010 “Radiation Therapy for Breast Cancer”. University of Maryland Department

of Radiation Oncology. 2010 “Overview of the Use of Partial Breast Radiation in the Treatment of Early Stage Breast Cancer”. University of Maryland, Department of Radiation Oncology 2010 “Radiation Therapy for Breast Cancer, What’s new in 2010? University of

“Maryland, Department of Radiation Oncology

Steven J. Feigenberg, MD

-7-

2010 “Breast Cancer Panel Discussions (Breast Evaluation and Treatment)”. University of Maryland School of Medicine.

2010 “Radiation Therapy for Lung Cancer: What’s new in 2010? University of Maryland, Department of Radiation Oncology

2010 “What is the role of post-operative radiation therapy in Non-Small Cell Lung Cancer”. University of Maryland, Department of Radiation Oncology

2010 “Lung Cancer: Round table discussion”. University of Maryland, Department of Radiation Oncology.

2010 “Head & Neck: Round table discussion”. University of Maryland, Department of Radiation Oncology.

2011 “Best of ASTRO 2010 – SBRT & Lung Cancer. University of Maryland, Department of Radiation Oncology’s Annual ASTRO Review Course, January 6, 2011.

2011 “Round table discussion on early stage breast cancer” University of Maryland, Department of Radiation Oncology.

2011 “Round table discussion on locally advanced breast cancer” University of Maryland, Department of Radiation Oncology.

2011 “Round table discussion on locally advanced lung cancer” University of Maryland, Department of Radiation Oncology.

2012 “The role of radiotherapy in the management of basal cell and squamous cell carcinomas of the skin.” University of Maryland, Department of Radiation Oncology.

2012 “Basics of Radiation Oncology: What a surgeon needs to know?” University of Maryland, Department of Surgery

2012 “FDG PET scans: The radiation oncology perspective.” University of Maryland, Diagnostic Radiology and Nuclear Medicine.

2012 “Innovations in Radiation Oncology in the Treatment of Cancer Workshop”, Introduction to Clinical Medicine, 1st and 2nd year medical students

Radiation Oncology Mock Oral Preparatory Exams 2002 - 2009 Thoracic malignancies, Head and Neck malignancies, CNS/pediatric

8 residents/yr – 0.75 hours per resident/yr plus preparation at FCCC. 2009 - 2011 Breast Cancer, Thoracic malignancies, Head and Neck malignancies

4 residents/yr – 1hr per resident/yr in didactic format at University of Maryland. 2009 - 2011 Breast Cancer, Thoracic malignancies, Head and Neck malignancies

4 – 6 post-graduate residents/yr – 1 hr per resident/yr on a one-one basis for John Hopkins, University of Maryland and Fox Chase Cancer Center graduates.

Student Research Sponsorships/Mentorships 2005 LinnaLi, 3rdyr medical student, retrospective chart review

Three-Dimensional Treatment Planning Decreases the Risk of Feeding Tube Dependency Following Definitive Radiation for Locally Advanced Head and Neck Cancer.

Steven J. Feigenberg, MD

-8-

Poster presentation at the Annual Meeting of ASTRO in Philadelphia. Int J RadiatOncolBiol Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S452.

2009 Kruti Patel, 4thyr medical student, retrospective chart review.

Predictors of radiographic pneumonitis following Stereotactic Body Radiotherapy.

Poster presentation at the ASTRO Translational Advances in Radiation Oncology and Cancer Imaging meeting, September 11-12, 2009, St. Louis, MO.

2009 Matthew Johnson, 4thyr medical student, wrote case report.

Head and Neck Cancer Metastasis to the Percutaneous Endoscopic Gastrostomy (PEG) tube site: A Report of Two Cases. Journal of Radiotherapy in Practice, Cambridge University Press, 2010, 9: 261-264.

2009 Ben Weinberg, 4thyr medical student, retrospective chart review.

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical outcomes and relation of parotid gland volume with xerostomia.

Poster presentation at the American Head and Neck Society Meeting (AHNS), April 28 – 29, 2010, Las Vegas, Nevada

2009 Anna Strongin, 3rdyr medical student, retrospective chart review.

CT scans are an accurate assessment of Tumor Size in Early Breast Cancer.

Poster presentation at San Antonio Breast Cancer Symposium, December 2010, San Antonio, TX.

2010 Charlie Rutter, 4thyr medical student, retrospective chart review.

Heterogeneity Corrections Alters the Delivered Dose, Potentially Impacting Complications in Patients Treated with Stereotactic Body Radiotherapy (SBRT) of the Lung.

Poster presentation at the 52nd Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), San Diego, CA October 31 - November 4, 2010.

2010 Melissa Liriano, 2ndyrMD PhD candidate—Clinical Shadowing for 6 months

during PhD. 2010 - 2012 Melissa Liriano, 2ndyr MD PhD candidate, ASTRO Minority Summer

Fellowship Award winner. Conducting a retrospective chart review on locally advanced lung cancer patients treated with combined chemotherapy and radiation therapy with or without surgery.

Steven J. Feigenberg, MD

-9-

Poster Presentation at 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6th to 8th, 2012.

Poster discussion presentation at the 54th Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MS, October 27th to 30th, 2012.

2011 - 2012 Akiva Diamond, 2ndyr medical student, retrospective chart review.

Evaluating the role of aggressive local therapy for lung cancer in the setting of metastatic disease to the brain

2011 - 2012 Musaddiq Awan, 3rdyr medical student, retrospective chart review.

Evaluating the role of MRI and ultrasound in the management of breast cancer patients who could be treated with partial breast radiation therapy. Poster presentation at the 54th Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MS, October 27th to 30th, 2012. Manuscript published: Awan M, Cohen R, Campassi C, Tkaczuk K, Kesmodel SB and Feigenberg SJ. MRI and it’s impact on partial breast radiation. Applied Radiology (in press).

2011- 2012 Bertram Maidment, 4thyr medical student, retrospective chart review.

Evaluating the role of thin sliced MRI of the brain for patients with brain metastases: Predictors of additional metastases on thin sliced MRI.

2012 Eric Christensen, 3rd year medical student, retrospective analysis of pre-operative APBI study. Evaluating the role of infiltrating T cells in and around the tumors as altered by pre-operative radiotherapy Poster presentation at the 54th Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MS, October 27th to 30th, 2012.

2013 Sarah Nicholas, 3rd year medical student, retrospective chart review.

Evaluating the patterns of failure for patients with locally advanced lung cancer. AACR/ASCO Workshop on Methods in Clinical Cancer Research (Primary Mentor) 2008 Navesh Sharma, DO, PhD develop the following protocol concept phase I

protocol combining an mTOR inhibitor, erlotinib and involved field radiotherapy in the re-irradiation setting for patients with squamous cell carcinoma of the head and neck.

Steven J. Feigenberg, MD

-10-

2009 Josh Silverman, MD, PhD develop the following protocol concept phase I protocol dose escalation protocol for medically inoperable renal cell carcinoma using the novel PET tracer 124I-G250 for evaluating treatment volume and response to therapy.

2010 Zain Husain, MD develop the following protocol concept phase I protocol using SBRT

for high risk lung cancer patients prior to planned sublobar resection

Radiation Oncology Resident/Fellow Research Sponsorships

2003 Shelly Hayes, retrospective chart review. Are there any prostate cancer patients without high risk features who need long term androgen deprivation with external beam radiation therapy? A recursive partitioning analysis.

Oral presentation. ASTRO Annual Meeting. Int J RadiatOncolBiolPhys Vol. 60(1),Suppl., Abstract 2199, p. S455, 2004.

2003 Rojymon Jacob, retrospective chart review. Is there a role for digital rectal examination in the follow-up of patients with prostate cancer treated with radiotherapy in the PSA era?

Poster presentation. ASTRO Annual Meeting. Int J RadiatOncolBiolPhysVol 60(1), Suppl., Abstract 2233, p. S476, 2004.

2005 Kim Brown, retrospective chart review.

Pneumonectomy following induction chemoradiotherapy (CRT) in NSCLC at Fox Chase Cancer Center (FCCC): peri-operative mortality rate is lower than expected.

Poster discussion. ASCO Annual Meeting, Atlanta, GA. June 2-6, 2006.J ClinOncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7107.

2005 - 2008 David D’Ambrosio, retrospective chart review.

Weight loss can significantly alter Tumor Coverage during treatment with IMRT: Implications for Adaptive Radiotherapy for Head and Neck Cancer.

Poster Presentation at the 88th Annual Meeting of the American Radium Society, Maui, Hawaii, 2006.

Published case report on Unexpected Dementia following Prophylactic Cranial Irradiation for small cell lung cancer. J NeuroOncology 85(1) 77-79, 2007.

Lateral cord blocks for treatment of head and neck malignancies with radiotherapy increase the risk for esophageal stricture.

Steven J. Feigenberg, MD

-11-

Oral presentation at the American Radium Society at the 90thAnnual Meeting.Oncology Vol. 22 No. 4, Suppl. 1, (S48) 2008. Travel Grant Award Winner Essay Award winner

2006 Edna Berman, case report.

Published a case report on Radiation-Induced tumor following stereotactic radiosurgery for an arteriovenous malformation. J Neurosurgery61(5) E1099, 2007. Discussion E1099.

2007-2009 Linna Li, retrospective chart review and SEER database projects.

Mortality from cerebrovascular disease after head and neck irradiation. Oral presentation at the 90thAnnual Meeting of the American Radium Society. Oncology Vol. 22 No. 4, Suppl. 1, (S44) 2008.

The use of an intermediate risk volume dose constraint in head and neck IMRT can increase hot spots.

Poster Presentation at the 91stAnnual Meeting of the American Radium Society. April 25-29, Vancouver, BC, Canada.

Second Primary Lung Cancer in Non Small Cell Lung Cancer Survivors: Implications for long term follow up and screening.

Poster Discussion at the 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009.

2007-2009 Navesh Sharma, retrospective chart review.

Low morbidity and excellent local control using image guided Stereotactic Body Radiation Therapy (IGSBRT) for lung tumors.

Poster presentation. ASTRO Annual Meeting. Int. J Rad OncolBiolPhys 72

(1),(S454),2008.

Tumor Histology and Initial SUV max predict for a greater than 55% decrease on post SBRT PET Scans: Implications in using PET as a surrogate for local control.

Oral presentation at the ASTRO Translational Advances in Radiation Oncology and Cancer Imaging meeting, September 11-12, 2009, St. Louis, MO.

Low Pretreatment PET SUV Predicts for Increased Local Failure Following Stereotactic Body Radiation Therapy for Lung Cancer.

Poster presentation at the 52nd Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO),San Diego,CA October 31- November 4, 2010.

Steven J. Feigenberg, MD

-12-

2007 Peter Morgan, retrospective chart review. A simple method to significantly reduce treatment time for head and neck IMRT.

Poster presentation. ASTRO Annual Meeting. Int. J Rad OncolBiolPhys

72(1),S598, 2008. 2007-2010 Aruna Turaka, retrospective chart review on Head and Neck Cancers treated

with IMRT. Increased loco-regional failures using Intensity-Modulated Radiation Therapy (IMRT) in the postoperative setting. Fox Chase Cancer Center, Philadelphia, PA.

Poster presentation at the American Head and Neck Society Meeting (AHNS), May 30- 31, 2009 Phoenix, Arizona. Receive “poster of Distinction”.

Manuscript published ahead of print in Am J ClinOncol. 2010 Dec; 33 (6): 599-603.

The use of a Low Neck Field (LNF) and intensity-modulated radiation therapy (IMRT): No clinical detriment of IMRT to an anterior LNF during the treatment of Head and Neck Cancer.

Poster presentation at the 51st Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), November 1-5, 2009, Chicago, IL.

Manuscript published in Int J RadiatOncolBiol Phys. 2011 Jan; 79 (1): 65-70. Epub 2010 Apr 10.

Predictors of Outcomes and Toxicities among the Postoperative Head and Neck Cancer Patients treated with Intensity Modulated Radiation Therapy (IMRT).

Oral presentation at the 2010 Multidisciplinary Head and Neck Cancer Symposium, Feb 25-27, 2010, Chandler, AZ.

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Oropharyngeal Carcinoma: Clinical outcomes and relation of parotid gland volume with xerostomia.

Poster presentation at the American Head and Neck Society Meeting (AHNS), April 28 – 29, 2010, Los Vegas, Nevada and the 52nd AAPM Annual Meeting in Philadelphia, PA, July 18-22, 2010.

Intensity-modulated radiation therapy (IMRT) for the Para-nasal sinus malignancies: Outcomes from Fox Chase Cancer Center (FCCC).

Steven J. Feigenberg, MD

-13-

Oral presentation at the 52nd AAPM Annual Meeting in Philadelphia, PA, July 18-22, 2010 and 52nd Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO),San Diego,CA October 31- November 4, 2010.

Manuscript on Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer. January 14, 2010 “Thyroid Science”, 5(1):CLS1-8, 2010.

2009-2011 Usama Mahmood, retrospective SEER project. Local Treatment Improves Outcome in Occult Primary Breast Cancer: A Surveillance Epidemiology and End Results Analysis. Poster discussion at the 2010 Annual ASTRO Meeting in October 2010.

Equivalent survival with breast-conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Oral presentation at the 2011 Annual ASCO Breast Cancer Symposium on September 8-10, 2011 in San Francisco, California. Project selected to receive the 2011 Breast Cancer Symposium Merit Award. Selected as one of only four presentations for the meeting's official Press Program. Equivalent survival with breast-conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Oral presentation at the 2011 Annual Meeting of ASTRO in Miami, Florida on October 2-6, 2011. Manuscript accepted on 10/29/11to International Journal of Radiation Oncology, Biology and Physics. Similar Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early Stage Breast Cancer

2010-2011 Zain Husain, retrospective chart review and SEER database projects. Low Pretreatment PET SUV Predicts for Increased Local Failure Following Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics Vol. 78, Issue 3, Supplement, Page S 525, 1 November 4, 2010

Risk of breast fibrosis following irradiation using a breast-specific SBRT system compared with conventional APBI.

Poster presentation at the 2011 Annual ASCO Breast Cancer Symposium on September 8-10, 2011 in San Francisco, CA.

Brachytherapy Based Accelerated Partial Breast Irradiation - A Patterns of Care Analysis with ASTRO Consensus Statement Groupings.

Steven J. Feigenberg, MD

-14-

Poster Presentation at the 2011 Annual Meeting of ASTRO in Miami, FL on October 2-6, 2011. Selected for Breast Cancer Achievement Award based on his interest in the field of breast cancer which funded all expenses to 13th Annual Lynn Sage Breast Cancer Symposium 2011

2010 -2012 Elizabeth Nichols, retrospective chart review.

Pre-operative therapy increases patient eligibility for accelerated partial breast irradiation (APBI) and decreases normal tissue exposure. Poster presentation at the 52nd Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), San Diego,CA October 31- November 4, 2010.

Manuscript accepted on 10/29/11to International Journal of Radiation Oncology, Biology and Physics.

Development of a Stereotactic Body Radiation Therapy System Dedicated to the Treatment of Early Breast Cancer.

Poster presentation at San Antonio Breast Cancer Symposium, December 2010, San Antonio, TX.

Pre-operative therapy increases patient eligibility for accelerated partial breast irradiation (APBI) and decreases normal tissue exposure.

Poster presentation at San Antonio Breast Cancer Symposium, December 2010, San Antonio, TX.

Marital Status is an Independent Predictor of Survival for Patients Undergoing Definitive Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

Poster Presentation at 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6th to 8th, 2012. Selected as one of 3 presentations to be highlighted in the Press Program for the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6-8, 2012.

Poster presentation at the 54th Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MS, October 27th to 30th, 2012.

2011-12 Drexel Hunter Boggs, retrospective chart review. Stereotactic Body Radiotherapy (SBRT) using Tomotherapy for Early Stage NSCLC: the utility of mid-fraction CT scans to assess intra-fraction tumor motion.

Steven J. Feigenberg, MD

-15-

Poster presentation at the 54th Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MS, October 27th to 30th, 2012.

Junior Faculty Research Mentors

2012 Josephine Feliciano, MD Assistant Professor in Medical Oncology - selected as K12 grant mentor for clinical trial design in Lung Cancer

Patent (application)

UMB Docket No. NM-2012-096: Quantitative evaluation of fractional regional ventilation using four-dimensional computed tomography Inventor: Nilesh Mistry, Warren D’Souza, Tejan Diwanji, Steven Feigenberg Grant Support

Active Grants 9/27/07-8/31/12 Steven Feigenberg, (Co-Investigator (4.09%); PI – Chris Amies, Cedric Yu, DSc Image-Guided Stereotactic Radiosurgery of Breast Cancer Xcision Medical Systems LLC (Prime NIH), Columbia, MD Annual Direct Costs: 12,781 Total Direct Costs: 12,781

7/1/11- 6/30/12 Steven Feigenberg, Principle Investigator

Maryland Industrial Partnership (MIPS) Image-Guided Stereotactic Radiosurgery of Breast Cancer

Xcision Medical Systems LLC (Prime NIH), Columbia, MD Annual Direct Costs: 89,999

Total Direct Costs: 89,999

9/1/11 - 7/31/12 Steven Feigenberg, Principle Investigator for subcontract NIAID grant number 5U19AI067773; PI – David Brenner Center for High-Throughput Minimally-Invasive Radiation Biodosimetry Local Protocol is titled:Radiationbiodosimetry in patients treated with radiation to prevent heterotopic ossification

Annual Direct Costs: 14,300 Total Direct Costs: 14,300

Steven J. Feigenberg, MD

-16-

Publications - Peer-reviewed Journal Articles

1. Feigenberg SJ, Marcus RB Jr, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Megavoltage Radiotherapy for Aneurysmal Bone Cysts. Int J RadiatOncolBiolPhys 49(5): 1243-1247, 2001.

2. Feigenberg SJ, Mendenhall NP, Reith JD, Ward JR, Copeland EM. Angiosarcoma after Breast Conserving Therapy: Role for Hyperfractionated Radiotherapy. Int J RadiatOncolBiolPhys 52(3): 620 – 626, 2002.

3. Feigenberg SJ, Mendenhall WM, Hinerman RW, Amdur RJ, Friedman WA, Antonelli PJ. Radiosurgery for Paragangliomas of the Temporal Bone. Head & Neck 24(4): 384 -389, 2002.

4. Feigenberg SJ, Marcus RB Jr, Zlotecki RA, Scarborough MT, Enneking WF. Pulmonary Metastases from Giant Cell Tumors of Bone: Three Cases of Whole-Lung Radiotherapy. Clinical Orthopaedics and Related Research 401: 202-208, 2002.

5. Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease Urinary Retention associated with Prostate Brachytherapy. Brachytherapy 2(2):103-107, 2003.

6. Ward JR, Feigenberg SJ, Mendenhall NP, Marcus RB Jr, Mendenhall WM. Radiation Therapy for Angiosarcomas. Head & Neck 25:873-878, 2003.

7. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Price RA. Radiation Therapy Dose Escalation for Prostate Cancer: A Rationale for IMRT. World J Urol 21(4): 200-208, 2003.

8. Monroe A, Feigenberg SJ, Mendenhall NP.Angiosarcomas after Breast Conservation.Cancer, 97: 1832-40, 2003.

9. Feigenberg SJ, Marcus RB Jr, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Radiation therapy for Giant Cell Tumors of Bone. Clinical Orthopaedics and Related Research 411:207-216, 2003.

10. Feigenberg SJ, Mendenhall NP, Benda RK, Morris CG. Postmastectomy Radiation Therapy: Patterns of Recurrence and Long-Term Disease Control using Electrons. Int J RadiatOncolBiolPhys, 56(3): 716-725, 2003.

11. Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB Jr, Friedman WA. Oligodendrogliomas: Does Deferring Treatment Compromise Outcome? Am J ClinOncol 26(3): e60–e66, 2003.

12. Pollack A, Hanlon AL., Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate Cancer Radiotherapy Dose Response: An Update of the Fox Chase Experience. J Urol 171:1132-1136, 2004.

13. Wang L, Movsas B, Jacob R, Fourkal E, Chen L, Price B, Feigenberg SJ, Konski A, Pollack A, Ma C. Stereotactic IMRT for Prostate Cancer: Setup Accuracy of a new Stereotactic Body Localization System. J ApplClin Med Phys, 5(2) 18-28, 2004.

14. Wang L, Jacob R, Chen L, Feigenberg SJ, Konski A, Ma C. Movsas B. Stereotactic IMRT for Prostate Cancer: Dosimetric Impact of Multileaf Collimator Leaf Width in the Treatment of Prostate Cancer with Intensity Modulated Radiotherapy. J ApplClin Med Phys, 5(2) 29-41, 2004.

15. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A Comparison of the Single vs. Double Factor High-Risk Stratification Models for Prostate Cancer Treated with 3D Conformal Radiotherapy.Int J RadiatOncolBiolPhys, 59: 380-385, 2004.

Steven J. Feigenberg, MD

-17-

16. Feigenberg SJ, Eisenberg D, Horwitz EM, Uzzo RG, Hanlon AL, Pollack A. What Pretreatment PSA warrants Long Term Androgen Deprivation? Int J RadiatOncolBiolPhys 61(4):1003-10, 2005.

17. Kramer NM, Horwitz EM, Cheng J, Babb JS, Ridge JA, Nicolaou N, Feigenberg SJ, Sherman EJ, Cohen RB, Damsker JA, Langer CJ. Toxicity and Outcome Analysis of Patients with Recurrent Head and Neck Cancer treated with Hyperfractionated Split-Course Re-irradiation and Concurrent Cisplatin and Paclitaxel Chemotherapy from two prospective Phase I and II studies. Head and Neck 27(4):406-15, 2005.

18. Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J RadiatOncolBiolPhys 63(5):1455-62, 2005.

19. Andrews SF, Horwitz EM, Feigenberg SJ,Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate cancer? Cancer 104(2):299-304, 2005.

20. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A. Long Term Androgen Deprivation increases Grade 2 or higher Late Morbidity in Prostate Cancer Patients treated with 3D Conformal Radiation Therapy. Int J RadiatOncolBiolPhys 62(2):397-405, 2005.

21. Feigenberg SJ, Lee WR, DeSilvio ML, Winter K, Pisansky TM, Watkins-Bruner D, Lawton C, Morton G, Baikadi M, Sandler H. Health–Related Quality of Life in Men receiving Prostate Brachytherapy on RTOG 98-05. Int J RadiatOncolBiolPhys 62(4):956-64, 2005.

22. Paskalev K, Feigenberg SJ, Wang L, Movsas B, Laske D, Ma C. A method for repositioning of stereotactic patients with the aid of real-time CT image guidance.Phys Med Biol 50:N201-207, 2005.

23. Paskalev K, Feigenberg SJ, Jacob R, McNeeley S, Horwitz E, Price R, Ma C, Pollack A. Target Localization for post-prostatectomy patients using CT and ultrasound image guidance. J ApplClin. Med. Phys 6(4):40-9, 2005.

24. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE; National Comprehensive Cancer Network (NCCN).Non-small cell lung cancer clinical practice guidelines in oncology. J NatlComprCancNetw. 2006 Jul; 4(6):548-82.

25. Feigenberg SJ, Eisenberg D, Horwitz EM, Uzzo RG, Hanlon AL, Pollack A. A PSA bounce greater than 1.5 ng/ml is clinically significant following external beam radiotherapy to prostate cancer. Am J ClinOncol 29(5):458-62, 2006.

26. Konski A, Horwitz E, Beck JR, Bruner DW, Feigenberg SJ, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat OncolBiolPhys 66(2):408-15, 2006.

27. Konski A, Watkins-Bruner D, Feigenberg SJ, Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate cancer. Cancer 106(1):51-7, 2006.

28. Pollack A, Hanlon A, Horwitz E, Feigenberg SJ, Konski A, Movsas B, Greenberg R, Uzzo R, Ma C, McNeeley S, Buyyounouski M, Price R Jr. Dosimetry and preliminary

Steven J. Feigenberg, MD

-18-

acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J RadiatOncolBiolPhys 64(2):518-26, 2006.

29. Wang L, Feigenberg SJ, Paskalev K, Chen L, Ma C. Benefit of 3-D image-guided stereotactic localization in the hypofractionated treatment of lung cancer. Int J RadiatOncolBiolPhys 66(3):738-47, 2006.

30. Berman E, Eade T, Shields C, Shields J, Ehya H, Feigenberg SJ, Konski A. Choroidal metastasis from carcinoid tumour.Diagnosis by needle biopsy and response to radiotherapy.Australasian Radiology 51(4) 398-402, 2007.

31. D’Ambrosio D, Glass J, Cohen R, Konski A, Feigenberg SJ. Unexpected Dementia following Prophylactic Cranial Irradiation for small cell lung cancer.JNeuroOncology 85(1) 77-79, 2007.

32. Berman E, Eade T, Brown D, Weaver M, Glass J, Zorman G, Feigenberg SJ. Radiation-Induced tumor following stereotactic radiosurgery for an arteriovenous malformation.J Neurosurgery61(5) E1099, 2007. Discussion E1099.

33. Feigenberg SJ, Paskalev K, McNeeley S, Horwitz E, Konski A, Wang L, Ma C, Pollack. A. Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation J ApplClin Med Phys, 8 (3), 2268, 2007.

34. D’Ambrosio D, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz E, Uzzo R, Pollack A, Buyyounouski M. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J RadiatOncolBiolPhys Volume 67 (4), 1082-1087,2007.

35. Langer C, Somer R, Litwin S, Feigenberg SJ, Movsas B, Maiale C, Sherman E, Millenson M, Nicolaou N, Huang C and Treat J. Phase I study of radical thoracic radiation, weekly Irinotecan and Cisplatin in locally advanced non-small cell lung carcinoma (LA-NSCLC). J Thoracic Oncol, 2(3):203-209, 2007.

36. Chang DT, Feigenberg SJ, Indelicato DJ, Mendenhall NP, Morris CG, Lightsey J, Grobmyer SR, Copeland EM 3rd. Long-term outcomes in breast cancer patients with 10 or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. Int J RadiatOncolBiol Phys,67(4):1043-1051, 2007.

37. Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 178(5):1920-4, 2007.

38. Feigenberg SJ, Hanlon A, Langer C, Goldberg M, Nicolaou N, Millenson M, Coia L, Lanciano R and Movsas B. A phase II Trial of Concurrent Paclitaxel and Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Carcinoma. J ThoracOncol, 2(4):287-292, 2007.

39. Jin L, Wang L, Li J, L W, Feigenberg SJ, Ma C-M. Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using Monte Carlo dose calculations.Phys Med Biol.52:3549-3561, 2007.

40. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE; National Comprehensive Cancer Network (NCCN).Non-small cell lung cancer.JNatlComprCancNetw. Mar; 6(3):228-69, 2008.

Steven J. Feigenberg, MD

-19-

41. Eade TN, Ruth K, D’Ambrosio D, Feigenberg SJ, Buyyounouski MK, Uzzo RG, Pollack A and Horwitz EM. A comparison of acute and chronic toxicity for men with low risk prostate cancer treated with intensity modulated radiation therapy or I-125 permanent implant. Int J RadiatOncolBiolPhys 71(2) 338-45, 2008.

42. Wang L, Hayes S, Paskalev K, Jin L, Buyyounouski M, Ma M, Feigenberg, S.Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage. Radiotherapy and Oncology, Jun91(3):314-24. Epub 2008 Dec 26.

43. Rusthoven K, Kavanagh B, Cardenes H, Stieber V, Burri S, Feigenberg S,Chidel M, Pugh T, Franklin W, Kane M, Gaspar L, Schefter T. Mature Results of a Multi-Institutional Phase I/II trial of Stereotactic Body Radiation Therapy for liver metastases. Journal of Clinical Oncology Vol. 27 (10), 1572-1578, 2009.

44. Lango M, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J, Ridge J. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: Pattern of pathologic residual carcinoma and prognosis. Head & Neck Jan; 31 (3), 328-337, 2009.

45. Lango M, Egleston B, Ende K, Feigenberg S, D’Ambrosio D, Cohen R, Ahmad S, Nicolaou N, Ridge J. Impact of neck dissection on long-term feeding tube dependence in H&N Cancer patients treated with primary radiation or chemoradiation. Head & Neck Mar;32(3):341-7, 2009.

46. Turaka A, Tianyu L, JYu, JQ, Nicolaou N, Burtness B, Lango, MN, Ridge JA, Feigenberg, SJ. Intensity Modulated Radiation Therapy (IMRT for Thyroid Cancer. Thyroid Science 5(1); 1-8, January 2010.

47. Johnson M, Turaka A, and Feigenberg SJ. Head and Neck Cancer Metastasis to the Percutaneous Endoscopic Gastrostomy (PEG) tube site: A Report of Two Cases. Journal of Radiotherapy in Practice, Cambridge University Press, 2010, 9: 261-264.

48. Lango MN, Egleston B, Ende K, Feigenberg SJ, D’Ambrosio DJ, Cohen RB, Ahmad S, Nicolaou N, Ridge JA. Impact of Neck Dissection on Long-term feeding tube dependence in patients with Head and Neck Cancer Treated with Primary Radiation or Chemoradiation.Head& Neck, Vol. 32(3); 341-347, March 2010.

49. Cohen RJ, Sharma NK, Yu JQ, Wang L, Buyyounouski MK, Unger M, Borghei H, King E, Scott W, Callahan E.Movsas BJ, Feigenberg SJ. A Phase I radiation dose escalation of stereotactic body radiotherapy for malignant lung tumors. JBiSE 3(4); 351-358 April 2010.

50. Movsas B, Langer CJ, Ross HK, Wang L, Jotte RM, Feigenberg SJ, Xu F, Huang CH, Monberg MJ, Obasaju CK. Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed byGemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B unresectable Non-Small Cell Lung Cancer.J Thoracic Oncol, Vol, 5 (5); 673-679. May 2010.

51. Chen L, Paskalev K, Xu X, Zhu J, Wang L, Price RA, Hu W, Feigenberg SJ, Horwitz EM, Pollack A, Ma CM. Rectal Dose Variation During the Course of Image-Guided RadiationTherapy of Prostate Cancer.RadiotherOncol, Vol 95(2); 198-202, May 2010; [Epub, Mar 18, 2010].

52. Cohen RJ, Paskalev K, Litwin S, Price RA Jr., Feigenberg SJ, Konski AA. Esophageal Motion during Radiotherapy; Quantification and Margin Implications. Dis Esophagus, Vol 23(6); 473-479, August 2010. [Epub Jan 15, 2010].

Steven J. Feigenberg, MD

-20-

53. Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge, J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head and Neck Cancer. Int J RadiatOncolBiolPhys, Vol. 78(4); 1020-1025, November 15, 2010; [Epub Mar 16, 2010].

54. Andrew G, Lango M, Cohen R, Feigenberg SJ, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J and Ridge JA. Nonsurgical Management of Oropharyngeal, Laryngeal, and Hypopharyngeal Cancer: The Fox Chase Cancer Center Experience. Head & Neck, November 10, 2010.

55. Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. Am J ClinOncol,33 (6); 599-603, December 2010.

56. Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF during the treatment of Head and Neck Cancer. .Int J RadiatOncolBiolPhys, Vol 79(1): 65-70, January 2011; [Eup April 10, 2010].

57. Husain ZA, Mahmood U, Hanlon A, Neuner G, Buras R, Tkaczuk K, Feigenberg SJ. Accelerated partial breast irradiation via brachtherapy: A patterns-of-care analysis with ASTRO consensus statement groupings. Brachytherapy, June 10, 2011; [Epub ahead of print].

58. Husain ZA, Regine WF, Kwok, Y, Feigenberg SJ. Brain Metastases: Contemporary Management and Future Directions. The European Journal of Clinical & Medical Oncology. June 2011, 3(3). 38-45.

59. Zhu Z, Doss M, Tan H, Feigenberg S, Yu JQ. Inadvertent Intraarterial Injection of 18F-FDG: A case report and Literature Review of Hot Forearm and Hot Hand signs. J Nucl Med Technol. 2011 Aug 24. [Epub ahead of print].

60. Wang L, Feigenberg S, Fan J, Jin L, Turaka A, Chen L, Ma C-M. Target Relocalization Accuracy and PTV Margin Verification using Three-dimensional Cone-Beam Computed Tomography (CBCT) in Stereotactic Body Radiotherapy (SBRT) of Lung Cancers. J Appl Clin Med Phys. 2012 Mar 8;13(2):3708.

61. Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk KH, and Feigenberg SJ. Similar Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early Stage Breast Cancer. Int J RadiatOncolBiolPhys. 2012 Aug 1;83(5):1387-93. Epub 2012 Jan 31.

62. Feigenberg SJ, Campassi C, Sharma N, Yu JQ, Kesmodel SB, Patel R and Tkaczuk K. Integration of Modern Imaging into the Multidisciplinary Setting: The radiation oncology perspective. Applied Radiology (in press)

63. Nichols EM, Feigenberg SJ, Marter K, Cheston SB, Lasio G, Tkaczuk K, Kesmodel S, Buras R and Regine WF. Pre-operative Radiation Therapy Significantly Increases Patient Eligibility for Accelerated Partial Breast Irradiation using 3-D Conformal Radiotherapy. Am J Clin Oncol. 2012 Apr 30 [Epub ahead of print].

64. Awan M, Campassi C, Cohen R, Tkaczuk K, Kesmodel SB and Feigenberg SJ. MRI and it’s impact on partial breast radiation. Applied Radiology (in press).

Steven J. Feigenberg, MD

-21-

65. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg SJ, Konski AA, Stoyanova R, Movasas, B, Greenberg, RG, Uzzo, RG, Ma, C, Buyyounouski, MK. Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. Journla of Clinical Oncology, October 7, 2013 [Epub ahead of print].

Non-peer reviewed articles

1. Feigenberg SJ, Movsas B. Recent Advances in Radiotherapeutic Management of Locally Advanced Non Small Cell Lung Cancer. Diagnosis and Treatment of Lung Cancer Updates 4(3): 1-9, 2003.

2. Horwitz EM, Feigenberg SJ,UzzoRG.The Treatment of Non-Metastatic Prostate Cancer with External Beam Radiation Therapy. MinervaUrologica e Nefrologica.56(2) 173-89, 2004.

3. Konski A, Feigenberg SJ, and Chow E. Palliative Radiation Therapy.Seminars in Oncology, 32(2):156-64, 2005.

4. Scott WJ, Howington J, Feigenberg SJ, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition) Chest132(3Suppl):234S -242S, 2007.

Articles in preparation/submitted for publication

1. Turaka A and Feigenberg SJ. NOT THE TYPICAL BUTTERFLY. Manuscript submitted to “Clinical Nuclear Medicine”.

2. Rutter CE, Husain ZA, Naqvi, SA, Zhang B, Marter K, Koshy M, Dhople A, D’Souza WD and Feigenberg SJ. The Use of Heterogeneity Corrections and Its Impact on Delivered Dose in Patients Treated with Stereotactic Body Radiotherapy of the Lung. Manuscript submitted for publication to Int J RadiatOncolBiol Phys.

3. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, William F Regine WF and Feigenberg SJ. Evidence of Improved Outcomes with Occult Versus Known Primary Breast Cancer. Article in preparation.

4. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, William F Regine WF and Feigenberg SJ. Early Evidence of Increasing National Mastectomy Rates for the Treatment of Breast Cancer. Manuscript submitted for publication to Int J RadiatOncolBiol Phys.

5. Sharma NK, Silverman JS, Ruth K, Eade TN, Yu JQ, Lally BE, Konski AA, Borghaei H, Buyyounouski MK, Wang L, Scott W, Movsas B and Feigenberg SJ. FDG-PET scans following SBRT: An early surrogate of response. Manuscript submitted for publication to Int J RadiatOncolBiol Phys.

6. Husain Z, Sharma N, Hanlon AL, Buyyounouski M, Mirmiran A, Dhople A, Turaka A, Chen W, Yu JQ, and Feigenberg SJ. Low Pretreatment PET SUV Predicts for Increased Local Failure Following Stereotactic Body Radiation Therapy for Lung Cancer. Manuscript submitted for publication to Int J RadiatOncolBiol Phys.

7. Morgan M, Nichols E, Buras R, Citron W, Drogula C, Bao T, Kesmodel S, Chumsri S, Tkazcuk KH, Regine WF, and Feigenberg SJ. Preliminary results of a prospective feasibility study testing preoperative accelerated partial breast radiotherapy (APBI) using 3 dimensional conformal radiotherapy (3D CRT). Article in preparation.

Steven J. Feigenberg, MD

-22-

8. Feigenberg SJ, Diwanji T, Sharma N, Mistry N and D’Souza W. Integration of Modern Imaging in Radiation Oncology. Manuscript being prepared for submittal to Applied Radiology.

Book Chapters

1. Feigenberg SJ, Pollack A, Price RA, McNeeley SW, Horwitz EM. Prostate. In: KS Clifford Chao, S. Apisarnthanarax, G Ozyigit (eds). Practical Essentials of Intensity Modulated Radiation Therapy. Second Edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2004.

2. Pollack A., Price R, Dong L, Feigenberg SJ, Horwitz E. Intact Prostate Cancer: Overview In: AJ Mundt, JC Roeske (eds), Intensity Modulated Radiation Therapy: A Clinical Perspective. BC Decker, Inc, ON, Canada 2005, pp 436-448.

3. Horwitz EM, Feigenberg SJ, Pollack A. Initial management of high risk early stage prostate cancer: Radiation. In: Kirby RS, Partin AW, Feneley M and Parsons JK (eds). Prostate Cancer – Principles and Practice. Boca Raton: Taylor & Francis, 2006, pp 855-863.

4. Price RA, Horwitz EM, Feigenberg SJ, Pollack A. Intact prostate cancer: Case Study. In: AJ Mundt and JC Roeske (eds), Intensity Modulated Radiation Therapy: A clinical Perspective. BC Decker, Inc, ON, Canada, 2006, pp 459-463.

5. Buyyounouski MK, Horwitz EM, Price RA, Feigenberg SJ, Pollack A. Prostate IMRT. In: Image Guided IMRT. T. Bortfeld, R. Schmidt-Ullrich, W de Neve (eds), Springer-Verlag Heidelberg, Germany, 2006, pp 391-410.

6. Feigenberg SJ, Lango, M, Ridge, JandGlisson B. in: Cancer Management: A Multidisciplinary Approach, Chapter 4: Head and neck tumors. Editors: Richard Pazdur, Kevin Camphausen, William Hoskins, LawrenceWagman. Melville, NY. 11th Edition, 2008.

7. Feigenberg SJ, Lango, M, Ridge, JandGlisson B. in: Cancer Management: A Multidisciplinary Approach, Chapter 1: Head and neck tumors. Editors: Richard Pazdur, Kevin Camphausen, William Hoskins, LawrenceWagman. Melville, NY. 12th Edition, 2009.

8. Feigenberg SJ, Lango, M, Ridge, J and Glisson B. in: Cancer Management: A Multidisciplinary Approach, Chapter 1: Head and neck tumors. Editors: Richard Pazdur, Kevin Camphausen, William Hoskins, LawrenceWagman. Melville, NY. 13th Edition, 2010.

9. Feigenberg SJ, Lango, M, Ridge, J and Mehra R. in: Cancer Management: A Multidisciplinary Approach, Chapter 1: Head and neck tumors. Editors: Richard Pazdur, Kevin Camphausen, William Hoskins, LawrenceWagman. Melville, NY. 14th Edition, 2011.

10. Pollack A, Li T, Buyyounouski M, Horwitz E, Price R, Stoyanova R, Feigenberg SJ, Konski A and Ma C. Hypofractionation for Prostate Cancer: The Fox Chase/University of Miami Experience. 2011 (in press)

11. Feigenberg SJ, Mutaf Y, Yu CX and Regine WF.in: Principles and Practice of Stereotactic Radiosurgery, 2nd Edition, Editors: Lawrence Chin and William Regine.

Steven J. Feigenberg, MD

-23-

Stereotactic Body Radiation Therapy for Breast Cancer using The GammaPodTM System, 2012 (in press).

12. Feigenberg SJ, et. al. in: Principles and Practice of Stereotactic Radiosurgery, 2nd Edition, Editors: Lawrence Chin and William Regine. Stereotactic Body Radiation Therapy, 2012 (in press).

13. Feigenberg SJ, Lango, M, Ridge, J and Mehra R. in: Cancer Management: A Multidisciplinary Approach, Chapter 1: Head and neck tumors. Editors: Richard Pazdur, Kevin Camphausen, William Hoskins, LawrenceWagman. Melville, NY. 15th Edition, 2012.

Letters to the editor

1. Hinerman RW, Mendenhall WM, Amdur RJ, Feigenberg SJ. Comment on Chemodectomas. Head & Neck, 24(4): 338 – 339, 2002. Editorial

2. Buyyounouski M, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, Pollack A. Letter to the Editor RE: “Erectile dysfunction and radiation dose to penile base structures: a lack of correlationʺ.Int J RadiatOncolBiolPhys 60:1664-1665, 2004.

3. Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG. Letter to the Editor, RE:“6-month androgen suppression plus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.ʺJAMA 292:2084-2085, 2004.

4. Feigenberg SJ, Lango M, Nicolaou N, Ridge J.Intensity modulated radiotherapy (IMRT) for early larynx cancer: Is there a role? Int J RadiatOncolBiol Physics 68(1):2-3, 2007. Editorial

5. Nichols EM, Regine WF, Feigenberg SJ. Letter to the Editor RE: Comparative Analysis of the Post-Lumpectomy Target Volume versus The Use of Pre-Lumpectomy Tumor Volume for Early-Stage Breast Cancer: Implications for the Future. Int. J RadiatOncolBiol Physics, 80(1);315-316; 2011.

Abstracts (not yet published) Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG. Prostate cancer treated with radiotherapy with or without androgen deprivation: The importance of the PSA nadir within 12 months. Abstract 4569. ASCO Annual Meeting 2004. Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. Identification of groups at risk for distant metastasis and death in men with rising PSA after radiotherapy for prostate cancer. Int J RadiatOncolBiolPhysVol 60(1), Suppl., Abstract 168, p. S233, 2004. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A. Post-treatment PSA values within 6 months of 3D conformal radiotherapy for prostate cancer predict for distant metastases. Int J RadiatOncolBiolPhys Vol. 60(1), Suppl. Abstract 170, p. S234, 2004.

Buyyounouski M, Hanlon AL, Horwitz EM, Feigenberg SJ, Al-Saleem TI, Pollack A. Pretreatment risk stratification of prostate cancer with percent positive prostate biopsy tissue obviates the need for clinical staging and identifies high risk disease suitable for treatment

Steven J. Feigenberg, MD

-24-

without androgen deprivation. Int J RadiatOncolBiolPhysVol 60(1), Suppl., Abstract 2164, p. S443, 2004. Hayes SB, Hanlon AL, Horwitz EM, Pollack A, Uzzo RG, Feigenberg SJ. Are there any prostate cancer patients without high risk features who need long term androgen deprivation with external beam radiation therapy? A recursive partitioning analysis.Int J RadiatOncolBiolPhys Vol. 60(1), Suppl., Abstract 2199, p. S455, 2004. Jacob R, Feigenberg SJ, Eisenberg D, Hanlon AL, Horwitz EM, Pollack A. Is there a role for digital rectal examination in the follow-up of patients with prostate cancer treated with radiotherapy in the PSA era? Int J RadiatOncolBiolPhysVol 60(1), Suppl., Abstract 2233, p. S476, 2004.

Wang L, Ma C, Paskalev K, Jacob R, Chen L, Feigenberg SJ, Movsas B, Pollack A. Feasibility study for clinical implementation of dose hypofractionation with IMRT for prostate cancer. Med. Phys. 31(6), AAPM 45th Annual Meeting, Abstract TUD-BRA-07, pp. 1877, 2004.

Wang L, Jacob R, Paskalev K, Ma C, Feigenberg SJ, Movsas B, Pollack A. Evaluating dosimetric benefit of image-guided stereotactic IMRT for prostate cancer through “real-time” dose reconstruction. Med. Phys 31(6), AAPM 45th Annual Meeting, Abstract #PO-T-165, pp 1885, 2004. Wang L, Feigenberg SJ, Paskalev K, Chen L, Qin L, Ma C, Movsas B. Optimal treatment planning of extracranial stereotactic conformal radiotherapy for medically inoperable lung cancer. Int J RadiatOncolBiolPhys 60(1) Suppl. P. S630-631, 2004.

Kavanaugh BD, Schefter TE, Cardenes HR, Timmerman RD, Feigenberg SJ, Stieber V, Nedzi LA, Gaspar LE. Biologically potent doses safely achieved in a multi-center trial of stereotactic radiation therapy for liver metastases. Int J RadiatOncBiolPhys 60(1) Suppl., p. S412-412, 2004. Feigenberg SJ, Morris CM, Wang L, Price R, Paskalev K, Konski A, Ma C. What is the optimal beam margin for extracranial stereotactic radiotherapy? Int J RadiatOncolBiolPhys 63(1), page S552, 2005. Snyder-Dougherty L, Sherman E, Riordan D, Nicolaou N, Feigenberg SJ, Lango M, Cohen RB, Horwitz EM, Langer CJ, Ridge JA. Cost Effectiveness of Amifostine for Prevention of Radiation-Induced Xerostomia.Abstract 5526, ASCO Annual Meeting, 2005.

Konski AA, Feigenberg SJ, Raysor S, Eisenberg D, Mirchandani I, Uzzo RG, Greenberg R, Horwitz E, Pollack A, Hanks G, Watkins-Bruner D. Twenty-five percent positive biopsy rate in a high risk prostate cancer screening program with a PSA <2.5 ng/ml. ASCO Annual Meeting 2005. Konski AA, Feigenberg SJ, Eisenberg D, Mirchandani I, Uzzo RG, Greenberg R, Horwitz E, Pollack A, Hanks G, Watkins-Bruner D. Younger age at diagnosis for African-American males

Steven J. Feigenberg, MD

-25-

with a family history of prostate cancer in a high-risk prostate cancer screening program. Prostate Cancer Symposium 2005.

Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. Predictors of hormone refractory disease in men treated with salvage androgen deprivation following definitive radiotherapy for prostate cancer. Int J RadiatOncolBiolPhys 63(1), page S296, 2005.

Nguyen KH, Horwitz E, Eisenberg D, Hanlon A, Feigenberg SJ, Pollack A. Does hyperinsulinemia in Type II diabetes mellitus influence disease presentation and long-term treatment outcomes of localized prostate cancer? Int J RadiatOncolBiolPhys 63(1), page S330, 2005.

Price RA, Paskalev K, Chen L, Wang L, Feigenberg S, Ma CC. MRI cine generated patient specific vs deep inspiration/expiration based PTVs in stereotactic radiotherapy for lung cancer. Int J RadiatOncolBiolPhys 63(1), pages S529-530, 2005.

Feigenberg SJ, Yu JQM, Eade T, Buyyounouski M, Wang L, Langer C, Scott W and B. Movsas. PET response following Stereotactic Body Radiotherapy for NSCLC correlates with Local Control. J ClinOncol, 2007 ASCO Annual Meeting Proceedings (Post Meeting edition). Vol 25, No. 18S (June 20 Supplement), 2006: 18013. Kirichenko AV, Ruth K, Horwitz EM, Buyyounouski MK, Feigenberg SJ, Chen DY and Pollack A. Intensity Modulated Radiation Therapy for Prostate Cancer: Preliminary Results on Treatment Morbidity Compared to 3-D Conformal Radiation Therapy. Int J RadiatOncolBiol Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S326. Li L, Feigenberg SJ, Hanlon AL, Ende K, Ahmed S, Nicolaou N, Horwitz EM, Langer CJ, Ridge JA and LangoM.Three-Dimensional Treatment Planning Decreases the Risk of Feeding Tube Dependency Following Definitive Radiation for Locally Advanced Head and Neck Cancer. Int J RadiatOncolBiol Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S452. Paskalev K, Feigenberg SJ, McNeeley S, Horwitz E, Price R, Konski A, Buyyounouski M, Ma C and Pollack A. CT-Based Daily Localization of Prostate Patients: Anatomy vs. Implanted Markers. Int J RadiatOncolBiol Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S621.

Brown K, Goldberg M, Scott W, Langer C, Feigenberg SJ. Pneumonectomy following induction chemoradiotherapy (CRT) in NSCLC at Fox Chase Cancer Center: peri-operative mortality rate is lower than expected. J ClinOncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7107.

Feigenberg SJ, Yu JQM, Eade T, Buyyounouski M, Wang L, Langer C, Scott W, Konski A and B. Movsas. FDG PET response by 3 months following Stereotactic Body Radiotherapy for NSCLC may be an early surrogate of local failure. Int J RadiatOncolBiol Physics, Volume 69(3),Supplement 1, November 2007, Pages S479-S480.

Steven J. Feigenberg, MD

-26-

Sherman E, Feigenberg SJ, Cohen R, Langer C, and JA Ridge.Cost-effectiveness of Amifostine for prevention of radiation-induced xerostomia.Int J RadiatOncolBiol Physics, Volume 69 (2), Supplement 1, October 2007, Page S142. Sharma NK, Ruth K, Konski AA, Buyyounouski MK, Nicolaou N, Lally BE, Movsas JQ, Feigenberg S. Low morbidity and excellent local control using image guided Stereotactic Body Radiation Therapy for lung tumors. Int. J Rad OncolBiolPhys 72 (1), (S454),2008.

Buyyounouski M, Li T, Al-Saleem T, Horwitz E, Konski A, Feigenberg S, Uzzo R, Pollack A. Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. Int. J Rad OncolBiolPhys 72(1), (S321-322), 2008. Lally B, Blackstock A, Buyyounouski M, Feigenberg S, Scott W, Thomas C, Konski A. The effect of race on combining surgery and radiation in locally advanced non-small cell lung cancer. Int. J Rad OncolBiolPhys 72(1),(S42), 2008. Morgan PB, Kurtizky N, Price RA, Nicolaou N, Ross E, Li S, Miuyamoto CT, Micaily B, Feigenberg S. A simple method to significantly reduce treatment time for head and neck IMRT. Int. J Rad OncolBiolPhys 72(1), S598, 2008. Karur V, Lally B, Scott W, Goldberg M, Millenson M, Feigenberg S, Movsas M, Mehra R, Langer C. Trimodality treatment using integratedchemoradiation with surgery for locally advanced non-small cell lung cancer. Int. J RadiatOncolBiolPhys 72(1) (S460), 2008. Feigenberg S, Hayes S, Flieder D, Milestone B, Li T, Buyyounouski M, Scott W. A pathologic and radiographic review of early stage non-small cell lung cancers to accurately define a clinical target: Implications for stereotactic body radiotherapy. Oncology Vol. 22No. 4, Suppl. 1,(S40) 2008. D’Ambrosio D, Feigenberg S, Li T, Nicolaou N, Li Linna,Horwitz E, Langer C, Ridge J, Lango M. Lateral cord blocks for treatment of head and neck malignancies with radiotherapy increase the risk for esophageal stricture. Oncology Vol. 22No. 4, Suppl. 1, (S48) 2008. Li L, Cohen R, Ridge J, Nicolaou N, Lango M, Feigenberg S, Morgan P. Mortality from cerebrovascular disease after head and neck irradiation. Oncology Vol. 22No. 4, Suppl. 1, (S44) 2008. Feigenberg SJ, Yu CX and Regine WF. Development of a Stereotactic Body Radiation Therapy System Dedicated to the Treatment of Early Breast Cancer. Int J RadiaOncol Biol. 78(3) supplement page S208.

Steven J. Feigenberg, MD

-27-

PRESENTATIONS

NATIONAL/INTERNATIONAL

1. Feigenberg SJ, Marcus RB Jr, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Megavoltage Radiotherapy for Aneurysmal Bone Cysts. Poster Presentation at the 41st Annual meeting of ASTRO. San Antonio, TX, Oct. 31 – Nov. 3, 1999.

2. Feigenberg SJ, Mendenhall NP, Carroll B, Lind DS, Copeland EM. Postmastectomy Radiation with Electrons. Poster Presentation at RSNA’s 86th Scientific Assembly and Annual Meeting Chicago, IL, Nov. 26 – Dec. 1, 2000.

3. Feigenberg SJ, Marcus RB Jr, Amdur RJ, Friedman WA. Oligodendrogliomas: Is Deferring Definitive Treatment an Option? Poster Discussion at the 43rd Annual meeting of ASTRO. San Francisco, CA, Nov. 4 – 8, 2001.

4. Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib Reduces Urinary Retention following Prostate Brachytherapy. Poster Discussion at RSNA’s 88th Scientific Assembly and Annual Meeting, Chicago, IL, Dec. 1 - 6, 2002.

5. Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A. Long Term Androgen Deprivation increases Late Morbidity in Prostate Patients treated with 3D Conformal Radiation Therapy. Oral Presentation at the 45th Annual meeting of ASTRO. Salt Lake City, UT, Oct. 19 – 23, 2003.

6. Feigenberg SJ, Eisenberg D, Horwitz EM, Uzzo RG, Hanlon AL, Pollack A. Post-treatment PSA values within 6 months of 3D Conformal Radiotherapy for Prostate Cancer predict of Distant Metastases. Oral Presentation at the 46th Annual meeting of ASTRO. Atlanta, GA, Oct. 3 – 7, 2004.

7. Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A, Hanks G. What pretreatment PSA necessitates the addition of Androgen Deprivation. Oral Presentation at the 86th Annual meeting of American Radium Society. Napa, CA, May 1 – 5, 2004.

8. Feigenberg SJ, Morris CM, Wang L, Price R, Paskalev K, Konski A and Ma C. What is the Optimal Beam Margin for Extracranial Radiotherapy? Poster Presentation at ASTRO’s 47th Annual Meeting, Denver, CO, October 16-20, 2005.

9. Feigenberg SJ, Eisenberg D, Horwitz EM, Uzzo RG, Hanlon AL, Pollack A. A PSA bounce greater than 1.5 ng/ml is clinically significant following external beam radiation for prostate cancer. Oral Presentation at the 87th Annual Meeting of the American Radium Society, Barcelona, Spain, April 30-May 4, 2005.

10. Feigenberg SJ. Obesity as measured by Body Mass Index appears to increase the risk of prostate cancer detection in the high risk population. Poster Presentation at GU Meeting at ASCO, Orlando, FL, February 17-19, 2005.

11. Feigenberg SJ, Hanlon A, Langer C, Goldberg M, Nicolaou N, Millenson M, Coia L, Lanciano R and Movsas B. A phase II Trial of Concurrent Paclitaxel and Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Carcinoma. Oral Presentation at ASTRO’s 48th Annual Meeting, Philadelphia, PA Nov 5-9, 2006.

Steven J. Feigenberg, MD

-28-

12. Feigenberg SJ, Wang L, Paskalev K, Konski A, Buyyounouski M and B. Movsas. Results of dose levels one and two of a Phase I study of Image guided Body Stereotactic Radiotherapy for Malignant Lung Tumors. Accepted for oral presentation. American Radium Society 88th Annual Meeting, Wailea, Hawaii May 6-11, 2006.

13. Feigenberg SJ, Yu JQM, Eade T, Buyyounouski M, Wang L, Langer C, Scott W, Konski A and B. Movsas. FDG-PET scan response by 3 months following stereotactic body radiotherapy for NSCLC may be an early surrogate of local failure. Poster Presentation at ASTRO’s 49th Annual Meeting. Los Angeles, CA. Oct. 27-31, 2007. Specially selected for ASTRO poster walk.

14. Feigenberg SJ, Yu JQM, Eade T, Buyyounouski M, Wang L, Langer C, Scott W and B. Movsas. PET response following Stereotactic Body Radiotherapy for NSCLC correlates with Local Control. Accepted for poster. ASCOAnnual Meeting, Chicago, IL. June 1-5, 2007.

15. Feigenberg S, Sharma N, Wang L, Cohen R, Buyyounouski M, Lally B, Movsas B. Phase I dose escalation trial of image guided Stereotactic Body Radiotherapy for lung tumors. Poster presentation at ASTRO’s 50thAnnual Meeting.Boston, MA September 21-24, 2008.

16. Feigenberg S. Final report of a Phase I dose escalation trial of stereotactic body radiotherapy (SBRT) for lung tumors. Poster Discussion at the 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009.

17. Feigenberg SJ, Yu CX and Regine WF. Development of a Stereotactic Body Radiation Therapy System Dedicated to the Treatment of Early Breast Cancer. Poster presentation at the 52nd Annual Meeting American Society for Therapeutic Radiology and Oncology (ASTRO),SanDiego,October 31- November 4, 2010.

18. Feigenberg SJ, Nichols E, Buras R, Citron W, Drogula C, Bao T, Kesmodel S, Chumsri S, Tkazcuk KH and Regine WF. Preliminary results of a prospective feasibility study testing preoperative accelerated partial breast radiotherapy (APBI) using 3 dimensional conformal radiotherapy (3D CRT). Poster presentation at the Annual Meeting of ASTRO in Miami, Florida on October 2-6, 2011.

19. Feigenberg SJ, Nichols E, Citron W, Drogula C, Bao T, Kesmodel S, Chumsri S, Tkazcuk KH and Regine WF. 25% complete response following preoperative accelerated partial breast radiotherapy (APBI) using 3 dimensional conformal radiotherapy (3D CRT): A prospective study. Poster presentation at the Annual Meeting of ASTRO in Boston, MS on October 27th to 30th, 2012.

PRESENTATIONS

REGIONAL

20. Prostate Cancer: All you need to know, The Brothers and Sisters against Cancer supported by the American Cancer Society.Gainesville, FL.April 12, 1999

21. Aneurysmal Bone Cysts.28th Annual University of Florida Radiation Oncology Clinical Research Seminar, Gainesville, FL, March 11-14, 1999.

22. Benign Giant Cell Tumors of Bone.28th Annual University of Florida Radiation Oncology Clinical Research Seminar, Gainesville, FL, March 11-14, 1999.

Steven J. Feigenberg, MD

-29-

23. Postmastectomy Radiation Therapy using Electrons.29th Annual University of Florida Radiation Oncology Clinical Research Seminar. Gainesville, FL, March 2-4, 2000.

24. Urinary and Rectal Morbidity following prostate brachytherapy.31st Annual University of Florida Radiation Oncology Clinical Research Seminar. Gainesville, FL, March 1-2, 2002.

25. Current and Future Strategies for Locally Advanced Lung Cancer, Lung Cancer: Challenges of Treatment and Symptom Management. Philadelphia, PA, October 29, 2002.

26. Stereotactic radiotherapy for malignant lung tumors. Lung Cancer: A Therapeutic Odyssey. Philadelphia, PA, September 28, 2004.

27. Obesity and Prostate Cancer: Is there any relationship? Fox Chase Cancer Center, Department of Nursing, November, 2004

28. New Treatment Options in Radiation of Head & Neck. Novel Approaches in the treatment of Head & Neck Cancer. Fox Chase Cancer Center, Philadelphia, PA, February 9, 2006.

29. Stereotactic Body Radiotherapy for malignant lung tumors. Lung Cancer: Detection to Survivorship. Philadelphia, PA. November 20, 2008.

30. Stereotactic Body Radiotherapy – ASTRO 2008 Update. Fox Chase Cancer Center Partners-Post-ASTRO Update 2008. Philadelphia, PA. December 9, 2008.

31. Stereotactic Body Radiation Therapy for Early Stage Lung Cancer. First Annual Fox Chase Cancer Center Advances in Thoracic Oncology. Philadelphia, PA. January 23, 2009.

32. Stereotactic Body Radiotherapy for Lung Cancer: Who, how and then what? 11th Annual University of Maryland Treatment of Thoracic Malignancies. October 30, 2009.

33. Lung Cancer and Stereotactic Body Radiotherapy. Mid Atlantic 2009 Best of ASTRO Review course. January 7, 2010.

34. Stereotactic Body Radiotherapy for Gastrointestinal Malignancies. University of Maryland Gastrointestinal Review course 2010. April 29, 2010.

35. Hepatocellular Carcinoma: What is the role of Radiation Therapy in 2010? University of Maryland, Department of Transplant – Grand Rounds, October 18, 2010.

36. Radiation Therapy for Breast Cancer in 2010. 8th Annual Breast Cancer Update: Screening, Diagnosis and Current Treatment. University of Maryland School of Medicine. October 22, 2010.

37. Radiation Therapy for Breast Cancer – Maryland General Hospital, Grand Rounds. October 27, 2010.

38. Radiation Therapy for Lung Cancer in 2010. Has really anything changed? University of Maryland, Pulmonary Department – Grand Rounds, November 15, 2010.

39. Stereotactic Body Radiosurgery: Potential for a paradigm shift in the Management of Early Breast Cancer. University of Maryland, School of Medicine, Department of Medical Oncology – Grand Rounds, November 29, 2010.

40. Stereotactic Body Radiotherapy: Clinical Utilization and Potential Avenues of Research. University of Maryland, School of Medicine, Grand Rounds – December 8, 2010.

41. Radiation Therapy for Breast Cancer: What’snew in 2010? University of Maryland School of Medicine, Department of Medical Oncology – Grand Rounds, December 18, 2010.

Steven J. Feigenberg, MD

-30-

42. Stereotactic Body Radiotherapy and Lung Cancer. Mid Atlantic 2010 Best of ASTRO Review course. January 6, 2011.

43. Partial Breast Radiation Therapy for Breast Cancer in 2011. 9th Annual Breast Cancer Update: Screening, Diagnosis and Current Treatment. University of Maryland School of Medicine. November 30, 2011.

44. Lung Cancer and Stereotactic Ablative Radiotherapy. Mid Atlantic Radiation Review course 2011. January 5, 2012.

45. Endobronchial Brachytherapy. Pulmonary Medicine Case Conference discussion. February 8, 2012.

INVITED PRESENTATIONS AND VISITING PROFESSORSHIPS

1. Postmastectomy Radiation Therapy using Electrons, The 11th Annual Radiation Oncology Therapists’ Seminar. Gainesville, FL, March 2-4, 2000.

2. Low Grade Gliomas, The 12th Annual Radiation Oncology therapists; Seminar. Gainesville, FL, March 2-3, 2001.

3. Radiation Therapy Techniques in Breast Cancer. The 13th Annual Radiation Oncology Therapists’ Seminar. Gainesville, FL, March 1-2, 2002.

4. Stereotactic Radiosurgery: Past, Present and Future, 12th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists. Philadelphia, PA, May 23, 2003.

5. MR Simulation for Radiation Treatment Planning. 5th Interventional Network Meeting. Antwerp, Belgium, August 25-29, 2003.

6. Stereotactic Radiosurgery in the Management of Malignant Brain Tumors, Temple University, Department of Neurosurgery Grand Rounds.Philadelphia, PA. 2004

7. Men at high risk for developing Prostate Cancer.” Prostate Cancer 2004: Challenges in Treatment. Philadelphia, PA, May 19, 2004.

8. Stereotactic Radiotherapy: It’s not only for the brain, 13th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists. Philadelphia, PA, May 28, 2004.

9. Organ Sparing treatment of invasive bladder cancer. Facts and Perspectives. International Conference on Current Issues in Onco Urology. Moscow, Russia, October 26, 2004.

10. T3 Prostate Cancer. Different Approaches: what is better? International Conference on Current Issues in OncoUrology. Moscow, Russia, October 27, 2004.

11. Radiation Therapy in the Management of Squamous Cell Carcinoma of the Head & Neck, Temple University, Department of Otolaryngology Grand Rounds. Philadelphia, PA.November February 2005.

12. Adaptive Radiation Therapy (ART) using CT in the Treatment Room. Siemens ART Forum. Denver, CO., October 14, 2005.

13. Stereotactic radiosurgery for brain metastases. 10th Annual Perspectives in Thoracic Oncology. New York, NY. November 4-5, 2005.

14. Radiotherapy in the Management of Squamous Cell Carcinomas of the Head and Neck. Training for New Hires for Bristol Myers Squibb. Princeton, NJ, February, 2006.

15. The Use of Gold Fiducials for Localization in Radiotherapy. The 15th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists. Philadelphia, PA, May 2006.

Steven J. Feigenberg, MD

-31-

16. Radiation Therapy for Lung Cancer in 2007. What’s new in Lung Cancer. William Smith Memorial Lecture Series, Asheville, NC, April 2007.

17. Respiratory Gating for Lung Cancer. 16th Annual Radiation Oncology Conference for Nurses, Therapists and Dosimetrists. Philadelphia, PA, May 25, 2007.

18. Extracranial Stereotactic Radiosurgery. A Phase I dose-escalation trial for malignant lung tumors. Philadelphia Cyberknife: Chronicles, Components and Case Studies. Philadelphia, PA, September 26, 2007.

19. Extracranial Stereotactic Radiosurgery: A Phase I dose-escalation trial for malignant lung tumors. Philadelphia cyberknife: Chronicles, Components and Case Studies, St. Davids, PA,September 27, 2007.

20. What’s new in Radiation Therapy for Lung Cancer in 2007. South Jersey Health Care, Millville, NJ. June 28, 2007.

21. A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-Small Cell Lung Cancer. First Wednesdays-Lung Cancer eJournal Club, Philadelphia, PA. December 5, 2007.

22. Stereotactic Body Radiotherapy for NSCLC: the past, present and future. Radiation Oncology Grand Rounds at Henry Ford Hospital, Detroit Michigan, Visiting Professor

23. Stereotactic Radiosurgery/Radiotherapy – Physician’s Perspective. 17th Annual Radiation Oncology Conference. Philadelphia, PA. May 22-24, 2008.

24. The role of FDG PET scan in staging of head and neck cancer. 7th International Conference on Head & Neck Cancer. San Francisco, CA. July 20-23, 2008.

25. The use of IMRT in Larynx Cancer. 7th International Conference on Head and Neck Cancer. San Francisco, CA. July 20-23, 2008.

26. Stereotactic Radiosurgery for Brain Metastasis. Temple University, School of Medicine, Neurology/Neurosurgery – Grand Rounds, Philadelphia, PA, 2009.

27. Stereotactic Body Radiotherapy: The Fox Chase Cancer Experience. The University of Maryland School of Medicine, Department of Radiation Oncology Grand Rounds, Baltimore, MD. June 2009. Visiting Professor.

28. Stereotactic Body Radiotherapy: Now that we have a new Hammer … York Cancer Center, Grand Rounds January 27, 2010.

29. Stereotactic Body Radiotherapy for Lung Cancer: The past present and future? East Coast Pulmonary Journal Club. Bethesda, MD May 16, 2012

30. Accrual Strategies and Perspectives from the RTOG Full Member Institution. University of Pennsylvania Department of Radiation Oncology Clinical Trials Course. Philadelphia, PA. June 11, 2012.

31. Stereotactic Body Radiotherapy: Lessons I’ve Learned over the last Decade. Wayne State University School of Medicine, Department of Radiation Oncology Grand Rounds, Detroit, MI. July 17, 2012. Visiting Professor.